The Asian Society for Psoriasis, Since 2019http://asp.umin.jp/***********************************************************************************************

2020 ASP Forum at “2020 ASP Forum and Cosentyx Grand Ceremony”
DateVenue
President

Secretary

Organization
Cooperation
Participants
Co-sponsoredDecember 26, 2020 (Sat)Fuli Hotel, Xi'an, China
WANG Gang, M.D. & Ph.D.
(Chairman and Professor, Department of Dermatology, Xijing Hospital, Fourth Military
Medical University & The Vice President of the ASP)
FAN Pingshen, M.D. & Ph.D.
(Associate Professor, Department of Dermatology, Xijing Hospital, Fourth Military
Medical University & The Director and the Secretary in China of the ASP)
Department of Dermatology at Xijing Hospital
The Asian Society for Psoriasis (The ASP)
About 850 persons (Onsite and Online)
Novartis Pharma K.K., China

Reporter
FAN Pingshen, M.D. & Ph.D. (The Director and the Secretary in China of the ASP)
The forum invited 6 experts of psoriasis from home and abroad, to bring the topics of Psoriasis treatment withBiologics. Dr. WANG Gang（The Vice President of the ASP, China）, Dr. MABUCHI Tomotaka (The Vice
President of the ASP, Japan), Dr. CHOE Yong Beom (The Director and the Secretary in Korea of the ASP,Korea) and Dr. TASI Dino (The Vice President and the Secretary in Chinese Taipei of the ASP, Chinese Taipei)
shared “Positioning and Challenges in the Future for the Treatment with Biologics” in different countries
separately. And Dr. YAMAMOTO Toshiyuki (The Director of the ASP, Japan) introduced “2019 PsA
Guideline”. 100 psoriasis experts attended the forum on site and was also watched by 750 audiences online.
Thanks to the guidance of Dr. OZAWA Akira (The President of the ASP, Japan) and Prof. Gang Wang as wellas the unconditional support and contribution of participating experts, this forum successfully stimulates theacademic exchange of Asian dermo-society which was well appreciated by participants.
Prof. Fan Pingshan (The Director and the Secretary in China of the ASP, China) introduced the Council
members of the Asian Society for Psoriasis, and the history of the ASP. The purpose of the society is to promoteinternational academic exchanges and to facilitate cooperation. The Asian Society for Psoriasis is also a younginternational academic organization, hoping to organize more dermatologists together and contribute to thetreatment for patients with psoriasis.
Dr. WANG Gang introduced the positioning of biological agents in the treatment of psoriasis in China and thecommon problems and counter measures in the application of biological agents. The emergence of biologicalagents is a revolutionary progress in the treatment of psoriasis. In the process of clinical diagnosis and treatment,
appropriate biological agents should be selected according to the specific situation of patients. At present, theindication of biologics on the market is moderate-to-severe plaque psoriasis. How to use biologics is the focus
and hot spot at present, which is worthy careful thinking so as to make a more suitable choice for patients.
Dr. MABUCHI Tomotaka introduced multicenter studies and genetic studies, and pathogenesis of psoriasis in***********************************************************************************************
1/ ６The Asian Society for Psoriasis, Since 2019http://asp.umin.jp/***********************************************************************************************

Japan. He also introduced the existing treatment methods of psoriasis in Japan which include 10 kinds ofbiologics such as Secukinumab and Etanercept. According to the current Japanese guidelines for the treatmentof psoriasis, in order to ensure the safety of usage, detection of infection should be carried out before and after
the use of biologics. Dr. Mabuchi also introduced Japan's public health care system. At present, Biologictreatment has been covered by NHS in Japan. The reimbursement is determined by patients’ age and income.
Most people only need to pay 30% of the treatment cost. And weight-adjusted dosage might be another choicefor patients under 60kg.
Dr. CHOE Yong Beom introduced in detail the considerations for the selection of different biological agents,
which is of great reference value in clinical work. South Korea is also a country with NHS, which adopts a threelevel hospital medical system, mainly receiving critically ill patients. The reimbursement rate can reach 50%,
and the reimbursement rate of psoriasis can reach a higher rate through rare disease reimbursement method.
We need to continue to explore the selection of biologics, indications and related safety issues. Although theproportion of medical insurance reimbursement is high in South Korea, the indications for biologics approvedby medical insurance are relatively strict.
Dr. TSAI Dino introduced the current situation and challenges of the treatment of psoriasis in special population,
including pediatric and pregnant patients. Dr. TSAI shared with us his valuable clinical experience in treatingthese special patients. At the same time, Dr. Cai also mentioned that Secukinumab indications of psoriasis inchildren has been approved in European and United States in 2020. Dr. Cai pointed out that the treatment ofspecial groups is a situation that dermatologists will encounter, and the basis of all is the trust between doctors
and patients.
Dr. YAMAMOTO Toshiyuki introduced the 2019 PsA Guideline of Japan. His speech reminds us to focus
deeper and kindlier than just examining the surface of the skin. PsA interprets the essence of "Beyond the SkinSurface". Dr. YAMAMOTO shared the characteristics of Japanese patients with PsA, compared
EULAR/GRAPPA recommendation with Japanese recommendation and displayed the common role ofdermatologists in the treatment of PsA in Japan. He also pointed out that Guideline is based on the evidence
available at the time of development, therefore should be updated along with new data such as real-world
efficacy and long-term data of safety.

***********************************************************************************************2/ ６

The Asian Society for Psoriasis, Since 2019http://asp.umin.jp/**********************************************************************************************************************************************************************************************3/ ６

The Asian Society for Psoriasis, Since 2019http://asp.umin.jp/**********************************************************************************************************************************************************************************************4/ ６

The Asian Society for Psoriasis, Since 2019http://asp.umin.jp/**********************************************************************************************************************************************************************************************5/ ６

The Asian Society for Psoriasis, Since 2019http://asp.umin.jp/**********************************************************************************************************************************************************************************************
6/ ６